Clinical efficacy of Atezolizumab and Bevacizumab in the treatment of initially borderline resectable advanced liver cancer
10.3760/cma.j.cn115610-20220120-00045
- VernacularTitle:阿替利珠单克隆抗体联合贝伐珠单克隆抗体治疗初始临界可切除中晚期肝癌的临床疗效
- Author:
Bowen YAO
1
;
Junxi XIANG
;
Xin ZHENG
;
Hao SUN
;
Wei YANG
;
Yuelang ZHANG
;
Feng YE
;
Dongli ZHAO
;
Yingmin YAO
;
Qingguang LIU
;
Cheng GUO
Author Information
1. 西安交通大学第一附属医院肝胆外科，西安 710061
- Keywords:
Liver neoplasms;
Conversion therapy;
Immune therapy;
Hepatectomy;
Multidisciplinary
- From:
Chinese Journal of Digestive Surgery
2022;21(2):303-306
- CountryChina
- Language:Chinese
-
Abstract:
Conversion therapy has become the core in the treatment of borderline resectable or unresectable liver cancer, which provides resectable opportunities for more advanced liver cancer patients. In accordance with the first-choice treatment regimen recommended by the guidelines, the authors reported a successful case of Atezolizumab and Bevacizumab (T+A regimen) conversion therapy. The patient with initially borderline resectable advanced liver cancer was performed liver segment resection sucessfully after conversion therapy, and non-tumor recurrence was observed at postoperative 9 months. Postoperative pathological examination showed combined hepatocellular-cholangiocarcinoma, which also indicated the important value of T+A regimen in the conversion therapy of combined hepatocellular-cholangiocarcinoma.
